Pure Bioscience Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis

Date: June 15, 2018
Pages: 50
US$ 499.00
Pure Bioscience Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

Pure Bioscience Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis
Pure Bioscience Due Diligence Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Pure Bioscience and its competitors. This provides our Clients with a clear understanding of Pure Bioscience position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Pure Bioscience that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Pure Bioscience. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Pure Bioscience financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Pure Bioscience competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Pure Bioscience business.

About Pure Bioscience

PURE Bioscience engages in the development and commercialization of silver ion antimicrobial technologies principally in the United States. The company offers silver dihydrogen citrate-based antimicrobials.

Bioscience Technologies

The company’s technology is a patented, aqueous antimicrobial called silver dihydrogen citrate (SDC). SDC is an electrolytically generated source of stabilized ionic silver that would serve as the basis for a range of products in various markets. It produces and markets pre-formulated, ready-to-use product for private label distribution, as well as SDC concentrate as an additive or raw material for inclusion in other companies’ products. It is producing SDC as a pharmaceutical ingredient, which is in clinical trials for multiple indications.

Principal Products and Markets

The company has the U.S. environmental protection agency (EPA) registration for six SDC-based products including its 2400-parts per million (ppm) technical grade SDC concentrate (trade name Axenohl); Axen and Axen30, its ready-to-use hard surface disinfectant products for commercial, industrial and consumer applications, including restaurants, schools, homes, and childcare and medical facilities; its Axen50 food contact surface sanitizer for sanitization of food contact surfaces and equipment in environments, such as farms, food processing plants, schools, hospitals, restaurants, and homes; and its SDC3A disinfectant and food contact surface sanitizer.

In April 2010, the EPA registered the disinfectant/sanitizer formula and it filed a federal sub-registration and subsequent state registrations for the disinfectant/sanitizer product to be sold as IV-7 ultimate germ defense for Food Contact Surfaces.

The company also produces an SDC-based antimicrobial product that provides the residual protection against norovirus. It markets the product to the cruise ship industry under the name Cruise Control. In addition, it manufactures a concentrated SDC-based water treatment product. It has supplied it through charitable organizations to provide water treatment solutions following international disasters, including the earthquake in Haiti.

The company has a development and licensing agreement for SDC-based products for human use with FTA Bioscience, LLC (FTA). In July 2010, based on preclinical data developed by FTA, it granted two product-specific licenses to FTA for the development of an SDC-based treatment for tinea unguium, also referred to as onychomycosis (nail fungus), as well as for tinea pedis (athlete’s foot). These licenses would allow FTA to file investigational new drug (IND) applications with the FDA and pursue clinical trials.


The company’s partners and distributors are marketing its SDC products to industrial and consumer markets. It sells SDC concentrate to partners that either resell the concentrate as an active ingredient or preservative in other companies’ products; blend the product into hard surface disinfectant products for sale to retail, commercial, and institutional customers; and develop formulations under a license granted by the company. In addition, it sells both bulk and individually bottled hard surface disinfectant products, both directly and through distributors, to retail, commercial, and institutional customers.

As of July 31, 2010, the company commenced sale of its hard surface disinfectants under its own label, IV-7 Ultimate Germ Defense (IV-7), through an alliance with a Dallas-based sales and marketing organization, Richmont Sciences, LLC (Richmont), to commercial distributors and commercial customers.

The company also sells SDC concentrate to BASF, who in turn resells the concentrate under BASF’s own brand names within the global personal care, household, and institutional markets. The company’s SDC is in various trials by third parties in the food processing and agriculture industries.

The company’s customers include BASF and Harmony Bioscience, which distribute hard surface disinfectant products to Asia.


PURE Bioscience was founded in 1992.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Pure Bioscience Direct Competitors
5.2. Comparison of Pure Bioscience and Direct Competitors Financial Ratios
5.3. Comparison of Pure Bioscience and Direct Competitors Stock Charts
5.4. Pure Bioscience Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Pure Bioscience Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Pure Bioscience Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Pure Bioscience Key Executives
Key Executives Biographies1
Key Executives Compensations1
Pure Bioscience Major Shareholders
Pure Bioscience History
Pure Bioscience Products
Revenues by Segment
Revenues by Region
Pure Bioscience Offices and Representations
Pure Bioscience SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Pure Bioscience Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Pure Bioscience Capital Market Snapshot
Pure Bioscience Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Pure Bioscience Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Pure Bioscience Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Pure Bioscience Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Pure Bioscience 1-year Stock Charts
Pure Bioscience 5-year Stock Charts
Pure Bioscience vs. Main Indexes 1-year Stock Chart
Pure Bioscience vs. Direct Competitors 1-year Stock Charts
Pure Bioscience Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Hand Sanitizers: Market Research Report US$ 4,950.00 Jan, 2017 · 274 pages

Ask Your Question

Pure Bioscience Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: